AZD0156: Selective ATM Kinase Inhibitor for Advanced Cancer Research

Principle Overview: Targeting ATM in the DNA Damage Response

The ataxia telangiectasia mutated (ATM) kinase is a master regulator of the DNA damage response, orchestrating cellular reactions to DNA double-strand breaks (DSBs), checkpoint control, and the maintenance of genomic stability. As a member of the PIKK family, ATM’s activity is pivotal in cell fate decisions, particularly in the context of oncogenesis and therapeutic resistance. AZD0156 (CAS: 1821428-35-6), supplied by APExBIO, is a potent and selective ATM kinase inhibitor distinguished by its sub-nanomolar inhibitory potency and over 1000-fold selectivity against other PIKK enzymes. Its oral bioavailability and robust preclinical performance make it a cornerstone for researchers unraveling the nuanced interplay of DNA damage response inhibition and metabolic adaptation in cancer therapy research.

Experimental Workflow: Enhancing Protocols with AZD0156

1. Reagent Preparation and Handling

• Solubilization: AZD0156 is optimally dissolved in DMSO (≥23.1 mg/mL) with gentle warming; moderate solubility in ethanol (≥5.49 mg/mL) allows alternative vehicle options for in vitro and in vivo experiments. The compound is insoluble in water.
• Storage: Store solid AZD0156 at -20°C. Prepare solutions immediately prior to use and avoid long-term storage to maintain activity and purity (>98% as confirmed by HPLC and NMR).

2. In Vitro Applications

• Pre-treat cancer cell lines with AZD0156 at concentrations ranging from 1–1000 nM to achieve robust ATM inhibition, adjusting based on cell type and assay sensitivity.
• Combine with DNA double-strand break-inducing agents (e.g., doxorubicin, ionizing radiation) to evaluate synergistic cytotoxicity, as demonstrated in recent synergy studies in high-grade serous ovarian cancer (Selective ATM Kinase Inhibition).
• Monitor downstream effects: ATM pathway inhibition can be validated through loss of p-ATM (Ser1981) and reduced phosphorylation of downstream targets such as Chk2 (Thr68) and KAP1 (Ser824).
• Metabolic assays (e.g., glucose and amino acid uptake, macropinocytosis quantification) are recommended to explore the metabolic vulnerabilities induced by ATM inhibition (see reference study Huang et al., 2023).

3. In Vivo Studies

• AZD0156 is orally bioavailable, supporting administration in animal models at 5–50 mg/kg, tailored to desired pharmacodynamic endpoints and tolerability.
• Evaluate tumor growth inhibition, DNA damage response markers, and metabolic adaptation (e.g., BCAA depletion in tumor microenvironment).
• Consider combinatorial strategies: pairing AZD0156 with macropinocytosis inhibitors or metabolic modulators may uncover novel therapeutic vulnerabilities, as reported in the reference study.

Advanced Applications and Comparative Advantages

AZD0156 stands out among ATM kinase inhibitors for its remarkable selectivity and bioavailability, enabling precise checkpoint control modulation and genomic stability regulation in diverse cancer models. Its utility extends beyond DNA double-strand break repair studies:

• Metabolic Adaptation: The work by Huang et al. (2023) reveals that ATM inhibition by AZD0156 drives increased macropinocytosis, promoting cancer cell survival under nutrient stress—linking DNA damage response inhibition to metabolic reprogramming and uncovering new therapeutic avenues.
• Synergy with DNA-damaging Agents: AZD0156 potentiates the efficacy of chemotherapeutics and radiation by impairing cancer cells’ ability to repair DSBs, as detailed in the thought-leadership article Potent ATM Kinase Inhibitor for Cancer Research. This demonstrates its value in overcoming therapy resistance.
• Genomic Stability and Beyond: As highlighted in A Selective ATM Kinase Inhibitor for Cancer Research, AZD0156 uniquely empowers investigation into how ATM suppression impacts not only DNA integrity but also cellular metabolism, expanding the scope of translational research.

Comparatively, while first-generation ATM inhibitors exhibited off-target effects or limited bioavailability, AZD0156’s >1000-fold selectivity and oral dosing capability enable more reliable in vivo modeling and translational studies. Its performance in combination regimens—demonstrating up to 2-fold increased tumor regression in preclinical models—sets a new benchmark for DNA damage response inhibitor research.

Troubleshooting and Optimization Tips

• Compound Stability: Avoid repeated freeze-thaw cycles and prolonged solution storage. Prepare aliquots for single-use to preserve inhibitor potency.
• Vehicle Selection: For cellular assays, ensure final DMSO concentrations do not exceed 0.1–0.5% to minimize cytotoxicity. For in vivo studies, confirm vehicle compatibility and consider suspensions in 0.5% methylcellulose or 10% ethanol/90% PEG400 for optimal bioavailability.
• Assay Sensitivity: Confirm ATM pathway inhibition by assessing multiple downstream markers (e.g., p-ATM, p-Chk2, p-KAP1). In cases of ambiguous results, verify batch integrity using HPLC or NMR purity data supplied by APExBIO.
• Cell Line Selection: Sensitivity to AZD0156 may vary by p53 and c-MYC status. As noted in Huang et al. (2023), ATM inhibition-driven metabolic effects are best characterized in models with wild-type p53.
• Combination Strategies: When combining with macropinocytosis inhibitors, stagger dosing to minimize overlapping cytotoxicity and better resolve synergistic effects.
• Data Interpretation: Metabolic changes (e.g., increased BCAA uptake) can confound viability readings. Include metabolic rescue controls (supplementation with BCAAs or essential amino acids) to validate ATM-specific effects.

Future Outlook: Expanding the Impact of Selective ATM Inhibition

AZD0156 is catalyzing a new era of research at the intersection of DNA repair, checkpoint control modulation, and cancer cell metabolism. Ongoing clinical investigations are poised to reveal its translational potential for patients with ATM-deficient or DNA repair-defective tumors. Future directions include:

• Biomarker Development: Identifying predictive markers of sensitivity or resistance to ATM inhibition will refine patient stratification in clinical trials.
• Combinatorial Therapeutics: Rational pairing with metabolic inhibitors or immune checkpoint blockade may further exploit vulnerabilities in ATM-inhibited cancer cells.
• Precision Oncology: As part of the next-generation toolkit, AZD0156 is positioned to enable new precision strategies, as discussed in the New Frontier of ATM Kinase Inhibition and Redefining DNA Damage Response.
• Integrated Metabolomics: Coupling AZD0156 with advanced metabolomic profiling will further elucidate the metabolic rewiring induced by ATM inhibition, opening paths to synthetic lethality and metabolic precision oncology.

In summary, AZD0156 from APExBIO is a transformative tool for molecular oncology, enabling researchers to dissect DNA damage response, checkpoint control, and metabolic adaptation with unparalleled specificity and translational relevance. By harnessing best-practice workflows and troubleshooting strategies, investigators can unlock the full potential of this potent ATM kinase inhibitor to drive the next wave of cancer therapy innovation.